Stoke Therapeutics (STOK) Change in Accured Expenses (2018 - 2026)

Stoke Therapeutics has reported Change in Accured Expenses for 9 years, with the latest figure at -$15.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 431.55% year-over-year to -$15.7 million; the trailing twelve-month figure through Mar 2026 stood at $829000.0 (down 91.5% YoY), and the FY2025 full-year result was $21.3 million, up 589.41% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$15.7 million, down from $8.9 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $8.9 million in Q4 2025, with the low at -$15.7 million in Q1 2026.
• Average Change in Accured Expenses over 5 years is $112941.2, with a median of $351000.0 recorded in 2023.
• Year-over-year, Change in Accured Expenses tumbled 677.39% in 2023 and jumped 751.67% in 2025.
• Tracing STOK's Change in Accured Expenses over 5 years: stood at $199000.0 in 2022, then plunged by 677.39% to -$1.1 million in 2023, then jumped by 289.64% to $2.2 million in 2024, then surged by 308.54% to $8.9 million in 2025, then plunged by 276.58% to -$15.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$15.7 million (Q1 2026), $8.9 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.

Peer Comparison